Preparing an ex vivo gene therapy process for process validationPublished: May 16, 2019
Vector Characterization & Validation
John Moscariello PhD is Senior Director, Viral Vector and Gene Editing Process Development for Juno Therapeutics, a Celgene Company. John joined Celgene in 2018 and serves as the Senior Director of Viral Vector and Gene Editing Process Development. Prior to joining Celgene, John was the Vice President of Process Development at AGC Biologics (formerly CMC Biologics) where his organization was responsible for all cell line development, upstream and downstream process development, analytical and formulation development, and technology transfer and technical manufacturing support. Prior to AGC Biologics, John held director-level positions at Amgen, focused on process development and characterization, clinical and commercial technology transfer and process validation. John has a Ph.D. in chemical and biological engineering from the University of Wisconsin-Madison and a bachelors of chemical engineering from the University of Delaware.DOI: 10.18609/cgti.2019.057
Citation: Cell & Gene Therapy Insights 2019; 5(4), 517-522.